Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MetMemory: Metformin for cognitive decline
NCT04511416Phase 3Active, not recruiting
- Sponsor
- Garvan Institute of Medical Research
- Start
- Jul 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of metformin in Mild Cognitive Impairment (MCI), sponsored by Garvan Institute of Medical Research. Started Jul 2022; status: active, not recruiting.
02
Drugs
metformin
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04511416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511416.